journal
MENU ▼
Read by QxMD icon Read
search

Infectious Diseases and Therapy

journal
https://www.readbyqxmd.com/read/28160269/infections-in-cancer-patients-with-solid-tumors-a-review
#1
REVIEW
Kenneth V I Rolston
Solid tumors are much more common than hematologic malignancies. Although severe and prolonged neutropenia is uncommon, several factors increase the risk of infection in patients with solid tumors, and the presence of multiple risk factors in the same patient is not uncommon. These include obstruction (most often caused by progression of the tumor), disruption of natural anatomic barriers such as the skin and mucosal surfaces, and treatment-related factors such as chemotherapy, radiation, diagnostic and/or therapeutic surgical procedures, and the increasing use of medical devices such as various catheters, stents, and prostheses...
February 3, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28078655/single-dose-oritavancin-compared-to-standard-of-care-iv-antibiotics-for-acute-bacterial-skin-and-skin-structure-infection-in-the-outpatient-setting-a-retrospective-real-world-study
#2
Patrick J Anastasio, Pete Wolthoff, Annmarie Galli, Weihong Fan
INTRODUCTION: Cost-containment strategies are shifting the treatment of acute bacterial skin and skin structure infections (ABSSSI) from inpatient to outpatient settings. Current standard of care (SoC) requires multiple-dose regimens, which are associated with high hospitalization rates and high costs. Oritavancin, a new single-dose antibiotic for ABSSSI, may be suitable for outpatient therapy. This analysis evaluates the effectiveness, costs, and resource utilization of oritavancin vs...
January 11, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28070870/defining-the-risk-and-associated-morbidity-and-mortality-of-severe-respiratory-syncytial-virus-infection-among-infants-with-congenital-heart-disease
#3
REVIEW
Paul A Checchia, Bosco Paes, Louis Bont, Paolo Manzoni, Eric A F Simões, Brigitte Fauroux, Josep Figueras-Aloy, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence-a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This fourth publication covers the risk and burden of RSV infection in infants with congenital heart disease (CHD). METHODS: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials...
January 9, 2017: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28039666/use-of-ceftaroline-fosamil-in-children-review-of-current-knowledge-and-its-application
#4
REVIEW
Juwon Yim, Leah M Molloy, Jason G Newland
Ceftaroline is a novel cephalosporin recently approved in children for treatment of acute bacterial skin and soft tissue infections and community-acquired bacterial pneumonia (CABP) caused by methicillin-resistant Staphylococcus aureus, Streptococcus pneumoniae and other susceptible bacteria. With a favorable tolerability profile and efficacy proven in pediatric patients and excellent in vitro activity against resistant Gram-positive and Gram-negative bacteria, ceftaroline may serve as a therapeutic option for polymicrobial infections, CABP caused by penicillin- and ceftriaxone-resistant S...
December 30, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/28013453/pk-pd-target-attainment-with-ceftolozane-tazobactam-using-monte-carlo-simulation-in-patients-with-various-degrees-of-renal-function-including-augmented-renal-clearance-and-end-stage-renal-disease
#5
Alan J Xiao, Luzelena Caro, Myra W Popejoy, Jennifer A Huntington, Ravina Kullar
INTRODUCTION: Ceftolozane/tazobactam is an antibacterial agent with potent in vitro activity against Gram-negative pathogens, including many extended-spectrum β-lactamase-producing Enterobacteriaceae and drug-resistant Pseudomonas aeruginosa. Because ceftolozane/tazobactam is primarily excreted renally, appropriate dose adjustments are needed for patients with renal impairment. Monte Carlo simulations were used to determine the probability of pharmacokinetic/pharmacodynamic target attainment for patients with varying degrees of renal function, including augmented renal clearance (ARC) and end-stage renal disease (ESRD) with hemodialysis...
December 24, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27943223/in-vitro-activity-of-ceftolozane-tazobactam-alone-or-with-an-aminoglycoside-against-multi-drug-resistant-pseudomonas-aeruginosa-from-pediatric-cystic-fibrosis-patients
#6
Aimee M Dassner, Christina Sutherland, Jennifer Girotto, David P Nicolau
INTRODUCTION: Gram-negative multi-drug resistance is an emerging threat among pediatric patients with cystic fibrosis (CF). Ceftolozane/tazobactam (C/T) is an extended-spectrum cephalosporin/beta-lactamase inhibitor combination that has been shown to maintain activity against MDR P. aeruginosa isolates. The understanding of C/T effectiveness in pediatric patients is extremely limited. Minimum inhibitory concentration (MIC) testing and time-kill analyses were performed to better understand the antimicrobial susceptibility and potential role of C/T...
December 9, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27913975/clinical-impact-of-an-antibiotic-stewardship-program-at-a-children-s-hospital
#7
Brian R Lee, Jennifer L Goldman, Diana Yu, Angela L Myers, Leslie M Stach, Erin Hedican, Mary Anne Jackson, Jason G Newland
INTRODUCTION: Antibiotic stewardship programs (ASP) improve appropriate antibiotic use. Data are limited on the clinical benefit of ASPs in children's hospitals. This study's objective was to determine the impact of an ASP on length of stay (LOS) and readmission rate among patients admitted to children's hospitals. METHODS: Data from a prospective-audit-with-feedback ASP were used to examine the ASP review characteristics, including antibiotic(s) prescribed, clinical indication, recommendations made by the ASP, and agreement with recommendations...
December 2, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27910000/a-review-of-experimental-and-off-label-therapies-for-clostridium-difficile-infection
#8
REVIEW
Csaba Fehér, Alex Soriano, Josep Mensa
In spite of increased awareness and the efforts taken to optimize Clostridium difficile infection (CDI) management, with the limited number of currently available antibiotics for C. difficile the halt of this increasing epidemic remains out of reach. There are, however, close to 80 alternative treatment methods with controversial anti-clostridial efficacy or in experimental phase today. Indeed, some of these therapies are expected to become acknowledged members of the recommended anti-CDI arsenal within the next few years...
December 1, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27900646/the-potential-of-omics-technologies-in-lyme-disease-biomarker-discovery-and-early-detection
#9
REVIEW
Alaa Badawi
Lyme borreliosis (LB) is the most prevalent arthropod-borne infectious disease in North America and many countries of the temperate Northern Hemisphere. It is associated with local and systemic manifestations and has persistent post-treatment health complications in some individuals. Innate and acquired immunity-related inflammation is likely to play a critical role in both host defense against Borrelia burgdorferi and disease severity. Large-scale analytical approaches to quantify gene expression (transcriptomics), proteins (proteomics) and metabolites (metabolomics) in LB have recently emerged with a potential to advance the development of disease biomarkers in early, disseminated and posttreatment disease stages...
November 29, 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27864751/defining-the-risk-and-associated-morbidity-and-mortality-of-severe-respiratory-syncytial-virus-infection-among-infants-with-chronic-lung-disease
#10
REVIEW
Bosco Paes, Brigitte Fauroux, Josep Figueras-Aloy, Louis Bont, Paul A Checchia, Eric A F Simões, Paolo Manzoni, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV evidence-a geographical archive of the literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This third publication covers the risk and burden of RSV infection in infants with chronic lung disease (CLD), formerly called bronchopulmonary dysplasia (BPD). METHODS: A systematic review was undertaken of publications between January 1, 1995 and December 31, 2015 across PubMed, Embase, The Cochrane Library, and Clinicaltrials...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27832502/a-retrospective-study-of-the-impact-of-rapid-diagnostic-testing-on-time-to-pathogen-identification-and-antibiotic-use-for-children-with-positive-blood-cultures
#11
Angela Fimbres Veesenmeyer, Jared A Olson, Adam L Hersh, Chris Stockmann, Kent Korgenski, Emily A Thorell, Andrew T Pavia, Anne J Blaschke
INTRODUCTION: Rapid identification of bloodstream pathogens provides crucial information that can improve the choice of antimicrobial therapy for children. Previous impact studies have primarily focused on adults. Our objective was to evaluate the impact of rapid testing in a children's hospital on time to organism identification and antibiotic use in the setting of an established antimicrobial stewardship program. METHODS: We conducted a retrospective study over three consecutive time periods (spanning January 2013-August 2015) as our hospital sequentially introduced two rapid testing methods for positive blood cultures...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27783223/value-of-treating-all-stages-of-chronic-hepatitis-c-a-comprehensive-review-of-clinical-and-economic-evidence
#12
REVIEW
Roberto Nuño Solinís, Patricia Arratibel Ugarte, Ander Rojo, Yuri Sanchez Gonzalez
INTRODUCTION: The goal of chronic hepatitis C (CHC) treatment is to achieve a sustained virologic response (SVR). The new generation of direct-acting antivirals (DAAs) offers 90-100% SVR rates. However, access to these treatments is generally limited to patients with advanced liver disease. The aim of this review is to provide an overview of the clinical and economic benefits of achieving SVR and to better understand the full value of CHC treatment in all stages of liver disease. METHODS: A comprehensive literature review was performed using the PubMed, Embase, and Cochrane library databases to identify articles examining the clinical, economic, and quality of life benefits associated with SVR...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27770261/epidemiology-and-recurrence-rates-of-clostridium-difficile-infections-in-germany-a-secondary-data-analysis
#13
Christoph Lübbert, Lisa Zimmermann, Julia Borchert, Bernd Hörner, Reinier Mutters, Arne C Rodloff
INTRODUCTION: Clostridium difficile infection (CDI) is the most common cause of health-care-associated infectious diarrhea. Recurrence rates are as high as 20-30% after standard treatment with metronidazole or vancomycin, and appear to be reduced for patients treated with fidaxomicin. According to the literature, the risk of CDI recurrence increases after the second relapse to 30-65%. Accurate data for Germany are not yet available. METHODS: Based on the research database of arvato health analytics (Munich, Germany), a secondary data analysis for the incidence, treatment characteristics and course of CDI was performed...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27718118/assessment-of-minimum-inhibitory-concentrations-of-telavancin-by-revised-broth-microdilution-method-in-phase-3-hospital-acquired-pneumonia-ventilator-associated-pneumonia-clinical-isolates
#14
Jennifer I Smart, Gordon Ralph Corey, Martin E Stryjewski, Whedy Wang, Steven L Barriere
INTRODUCTION: The broth microdilution method (BMD) for testing telavancin minimum inhibitory concentrations (MICs) was revised (rBMD) in 2014 to improve the accuracy, precision, and reproducibility of the testing method. The aim of this study was to determine the effect of the revised method on telavancin MIC values for Staphylococcus aureus (S. aureus) clinical isolates obtained from hospital-acquired pneumonia (HAP) patients. METHODS: Isolates from patients who participated in the phase 3 Assessment of Telavancin for Treatment of HAP Studies were retested using the rBMD method...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27714677/the-sustained-rotavirus-vaccination-impact-on-nosocomial-infection-duration-of-hospital-stay-and-age-the-rotabis-study-2005-2012
#15
Baudouin Standaert, Danielle Strens, Xiao Li, Nadia Schecroun, Marc Raes
INTRODUCTION: The benefits of rotavirus (RV) vaccination in developed countries have focused on reductions in mortality, hospitalization and medical visits, and herd protection. We investigated other aspects related to RV-induced nosocomial infection, duration of hospital stay, age shift, and sustained vaccine impact (VI) over time. METHOD: RotaBIS (Rotavirus Belgian Impact Study; ClinicalTrials.gov identifier, NCT01563146) annually collects retrospective data on hospitalization linked to RV testing in children up to 5 years old from 11 pediatric wards located all over Belgium...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27677264/pre-exposure-prophylaxis-for-hiv-prevention-why-what-who-and-how
#16
REVIEW
Olubanke Davies, Andrew Ustianowski, Julie Fox
Pre-exposure prophylaxis (PrEP) offers a promising new approach to HIV prevention. It is protective against HIV infection across populations and has few significant safety risks and little evidence of behavioural risk compensation. This article summarises the evidence behind HIV PrEP as an intervention, populations that may benefit, current guidelines and programmes, and the cost-effectiveness modelling of this strategy.
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27677263/atazanavir-and-cardiovascular-risk-among-human-immunodeficiency-virus-infected-patients-a-systematic-review
#17
REVIEW
Dominic Chow, Cecilia Shikuma, Corey Ritchings, Muxing Guo, Lisa Rosenblatt
INTRODUCTION: Patients with human immunodeficiency virus (HIV) infection have an increased risk of cardiovascular disease (CVD). While viral suppression with antiretroviral therapy decreases CVD risk overall, several studies have suggested that certain antiretrovirals, particularly certain protease inhibitors, may be associated with an increased relative risk of CVD. In AIDS Clinical Trials Group 5260 s, ritonavir-boosted atazanavir (ATV) was associated with slower atherosclerosis progression compared to ritonavir-boosted darunavir and raltegravir, potentially due to hyperbilirubinemia...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27628159/cross-sectional-survey-of-perceived-barriers-among-community-pharmacists-who-do-not-immunize-in-wayne-county-michigan
#18
Sarah E Kelling, Anthony Pattin, Abdulbaset Salim, Paul Kilgore, Steven R Erickson
INTRODUCTION: The goal of the study was to identify perceived barriers to implementation of vaccination services encountered by independent and small-chain community pharmacies in an urban setting. METHODS: Pharmacists in independent and small-chain pharmacies located in 29 Michigan ZIP codes were visited and asked to complete a 5- to 10-min semi-structured interview. RESULTS: A total of 93 independent and 12 small-chain pharmacies participated (n = 105; 61%)...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27628014/defining-the-risk-and-associated-morbidity-and-mortality-of-severe-respiratory-syncytial-virus-infection-among-preterm-infants-without-chronic-lung-disease-or-congenital-heart-disease
#19
REVIEW
Josep Figueras-Aloy, Paolo Manzoni, Bosco Paes, Eric A F Simões, Louis Bont, Paul A Checchia, Brigitte Fauroux, Xavier Carbonell-Estrany
INTRODUCTION: The REGAL (RSV Evidence-a Geographical Archive of the Literature) series provide a comprehensive review of the published evidence in the field of respiratory syncytial virus (RSV) in Western countries over the last 20 years. This second publication covers the risk and burden of RSV infection in preterm infants born at <37 weeks' gestational age (wGA) without chronic lung disease or congenital heart disease. METHODS: A systematic review was undertaken for articles published between January 1, 1995 and December 31, 2015...
December 2016: Infectious Diseases and Therapy
https://www.readbyqxmd.com/read/27565805/erratum-to-single-dose-oritavancin-treatment-of-acute-bacterial-skin-and-skin-structure-infections-solo-trial-efficacy-by-eron-severity-and-management-setting
#20
Daniel H Deck, Jennifer M Jordan, Thomas L Holland, Weihong Fan, Matthew A Wikler, Katherine A Sulham, G Ralph Corey
No abstract text is available yet for this article.
September 2016: Infectious Diseases and Therapy
journal
journal
48936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"